Tag: diagnostic assays

Health Insurers See Big Increase in Lab Utilization

CEO SUMMARY: In a recent public workshop, managed care executives revealed that the annual cost of outpatient laboratory testing is increasing at twice the rate of all other medical services. One big driver in the increased spending on lab testing is increased utilization of lab tests by physicians—particularly expensive molecular diagnostic assays and genetic tests.

View Article

Medicare Taken to Task about Molecular Test Pricing Method

EDITOR’S NOTE: Submitted by Lâle White, CEO of XIFIN, Inc., of Carlsbad, California, this letter describes the problems caused by the Medicare program’s failure, as of January 1, 2013, to be ready to process and reimburse lab test claims for more than 100 new molecular diagnostic CPT codes.

Dear Editor:

Everyone should read Scott Gottlieb, M.D.’s Forbes

View Article

March 25, 2013 “Intelligence: Late Breaking Lab News”

Last month, Dignity Health acknowledged that it is engaged in negotiations to sell its lab outreach business that is based in Stockton, California. The lab outreach program is known as HealthCare Clinical Laboratories and is associated with 294-bed St. Joseph’s Medical Center. The story surfaced after Dignity Health (formerly know as Catholic Healthcare West) notified

View Article

Ascend Clinical Acquires PathCentral Lab Business

CEO SUMMARY: Ascend Clinical and PathCentral see an opportunity to provide sophisticated services to community pathology groups. Ascend Clinical will expand the molecular diagnostic and gene sequencing business it is purchasing from PathCentral. PathCentral will concentrate on marketing its cloud-based anatomic pathology LIS solution and launching a pathology professional network early in 2013. Each company

View Article

November 19, 2012 “Intelligence: Late Breaking Lab News”

Only one clinical lab industry vendor made the inaugural list of the Modern Healthcare’s fastest- growing health companies. It was Sysmex America, of Mundelein, Illinois. Sysmex ranked number 26 on a list of 40 healthcare companies. Modern Healthcare reported that Sysmex’s 2011 revenues of $229.6 million represented a growth rate of 161.1%!
MORE ON: Sysmex
Such rapid

View Article

“Primary-Care Pathology” One Goal at Beth Israel

CEO SUMMARY: In a pioneering collaboration, the pathology department at Beth Israel Deaconess Medical Center in Boston, Massachusetts, will work with GenomeQuest, Inc., to perform whole genome sequencing of tumor specimens. GenomeQuest will handle sequencing, assembly, and annotation of the genetic data. BIDMC will analyze these whole human genome sequences to develop companion diagnostic tests

View Article